HIV and COVID-19: review of clinical course and outcomes.
HIV and COVID-19: review of clinical course and outcomes.
复制标题
DOI：
10.1080/25787489.2021.1975608
复制
发表时间：
2021-08
影响因子：
1.6
通讯作者：
Erlandson KM
中科院分区：
文献类型：
--
作者：
Barbera LK;Kamis KF;Rowan SE;Davis AJ;Shehata S;Carlson JJ;Johnson SC;Erlandson KM
背景：了解HIV和SARS-CoV-2之间的关系具有重要的公共卫生意义。目的：总结截至2021年7月15日发表的关于艾滋病毒感染者（PWH）中COVID-19的最新研究。研究方法：我们对PubMed、Scopus、预印本数据库（medRxiv、bioRxiv）以及使用与COVID-19（“COVID-19”或“SARS-CoV-2”或“冠状病毒”）和HIV（“HIV”或“人类免疫缺陷病毒”或“艾滋病”或“获得性免疫缺陷综合征”）相关的关键术语找到的出版物的参考文献进行了检索。我们总结了所有报道SARS-CoV-2和HIV合并感染数据或观点的文章。结论：尽管许多初始病例系列和队列研究发现，在PWH中，SARS-CoV-2感染或严重COVID-19结局的风险没有增加，但最近的研究表明，即使在艾滋病毒控制良好的情况下，严重COVID-19疾病进展的风险也会增加。这是否是由于PWH合并症和其他健康社会决定因素的患病率增加尚不清楚。这些相互矛盾的研究结果强调了在威尔斯亲王医院中继续进行COVID-19相关研究的必要性，以解决COVID-19疾病过程以及在威尔斯亲王医院中已经不成比例的现有合并症的恶化。
Background:Understanding the relationship between HIV and SARS-CoV-2 has important public health implications. Objective:To summarize current research on COVID-19 among people with HIV (PWH) as published through 15 July 2021. Methods: We conducted a search of PubMed, Scopus, preprint databases (medRxiv, bioRxiv), and the references of publications found using key terms relevant to COVID-19 (‘COVID-19’ OR ‘SARS-CoV-2’ OR ‘coronavirus’) AND to HIV (‘HIV’ OR ‘Human Immunodeficiency Virus’ OR ‘AIDS’ OR ‘Acquired Immunodeficiency Syndrome’). We summarized all articles that reported data or opinions on SARS-CoV-2 and HIV coinfection. Conclusions: Although many initial case series and cohort studies found no increased risk for SARS-CoV-2 infection or severe COVID-19 outcomes among PWH, recent studies have signaled an increased risk for severe COVID-19 disease progression even in the setting of well-controlled HIV. Whether this is due to the increased prevalence of comorbidities in PWH and other social determinants of health is unknown. These conflicting findings highlight the continued need for COVID-19 related research among PWH that addresses COVID-19 disease course as well as exacerbation of existing comorbidities already disproportionately represented among PWH.
登录
查看更多内容
DOI：
10.1016/j.cmi.2021.06.023
发表时间：
2021-11
期刊：
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
影响因子：
--
作者：
Berenguer J;Díez C;Martín-Vicente M;Micán R;Pérez-Elías MJ;García-Fraile LJ;Vidal F;Suárez-García I;Podzamczer D;Del Romero J;Pulido F;Iribarren JA;Gutiérrez F;Poveda E;Galera C;Izquierdo R;Asensi V;Portilla J;López JC;Arribas JR;Moreno S;González-García J;Resino S;Jarrín I
通讯作者：
Jarrín I
影响因子：
2.9
作者：
Alhumaid S;Mutair AA;Alawi ZA;Alhmeed N;Zaidi ARZ;Tobaiqy M
通讯作者：
Tobaiqy M
影响因子：
1.4
作者：
Bertolini M;Mutti MF;Barletta JA;Falak A;Cuatz D;Sisto A;Ragusa MA;Fernandez Claros NO;Rolón MJ
通讯作者：
Rolón MJ
影响因子：
6.4
作者：
Braunstein, Sarah L.;Slutsker, Jennifer Sanderson;Schillinger, Julia A.
通讯作者：
Schillinger, Julia A.
一项针对Lopinavir/Ritonavir，Lopinavir/Ritonavir Plus IFN-β-1A和羟基氯喹对Covid-19患者的开放标签随机对照试验。
DOI：
10.1016/j.cmi.2021.05.020
发表时间：
2021-12
期刊：
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
影响因子：
--
作者：
Ader F;Peiffer-Smadja N;Poissy J;Bouscambert-Duchamp M;Belhadi D;Diallo A;Delmas C;Saillard J;Dechanet A;Mercier N;Dupont A;Alfaiate T;Lescure FX;Raffi F;Goehringer F;Kimmoun A;Jaureguiberry S;Reignier J;Nseir S;Danion F;Clere-Jehl R;Bouiller K;Navellou JC;Tolsma V;Cabié A;Dubost C;Courjon J;Leroy S;Mootien J;Gaci R;Mourvillier B;Faure E;Pourcher V;Gallien S;Launay O;Lacombe K;Lanoix JP;Makinson A;Martin-Blondel G;Bouadma L;Botelho-Nevers E;Gagneux-Brunon A;Epaulard O;Piroth L;Wallet F;Richard JC;Reuter J;Staub T;Lina B;Noret M;Andrejak C;Lê MP;Peytavin G;Hites M;Costagliola D;Yazdanpanah Y;Burdet C;Mentré F;DisCoVeRy study group
通讯作者：
DisCoVeRy study group